pectril 500mg capsule
yung shin phils inc - cefalexin (as monohydrate) - capsule - 500mg
keto 30mg/ml solution for injection im/iv
yung shin phils inc - ketorolac trometamol - solution for injection im/iv - 30mg/ml
meloxin 7.5mg tablet
yung shin phils inc - meloxicam - tablet - 7.5mg
sovlan 1g + 200mg powder for injection iv
yung shin phils inc - amoxicillin , clavulanic acid - powder for injection iv - 1g + 200mg
anucare 107.5mg/18.8mg/12.5mg per g ointment ointment
yung shin (philippines), inc.; distributor: yung shin (philippines), inc. - zinc oxide , myroxylon balsamum var. pereirae (royle) harms (balsam of peru) resin , benzyl benzoate - ointment - 107.5mg/18.8mg/12.5mg per g ointment
granisetron hydrochloride injection, solution
yung shin pharmaceutical inc. co., ltd. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection usp is a serotonin-3 (5-ht3) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high- dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intravenous
granisetron hydrochloride injection, solution
yung shin pharmaceutical inc. co., ltd. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high- dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, usp is recommended even where the incidence of postoperative nausea and/or vomiting is low. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intra
felodipine tablet, extended release
yung shin pharmaceutical ind. co., ltd. - felodipine (unii: ol961r6o2c) (felodipine - unii:ol961r6o2c) - felodipine extended-release tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic cla
diclofenac sodium and misoprostol delayed-release- diclofenac sodium and misoprostol tablet, delayed release
yung shin pharmaceutical industrual co., ltd. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] - in the setting of coronary artery bypass g
bufencon injection
yung shin pharmaceutical (singapore) pte ltd - betamethasone dipropionate eqv betamethasone; betamethasone phosphate disodium eqv betamethasone - injection - 5 mg/ml - betamethasone dipropionate eqv betamethasone 5 mg/ml; betamethasone phosphate disodium eqv betamethasone 2 mg/ml